Immunoglobulin G concentration in bovine colostrum of Bos taurus x Bos indicus crosses during the first three days postpartum

El objetivo fue correlacionar la concentración de inmunoglobulina G (IgG) con la proteína, los minerales y el color en 69 calostros de bovinos de cruces Bos taurus x Bos indicus de un predio del sistema de producción doble propósito del piedemonte llanero en los primeros tres días posparto. La concentración de IgG en calostro presentó una correlación negativa con los días posparto, y una correlación positiva con el contenido de proteína, lactosa y sólidos en calostro entero. La correlación entre el color del calostro entero y la concentración de IgG fue positiva para el valor b* (r=0.182, p=0.024), localizado entre el rango de azules y amarillos. La concentración mediana de IgG para el día uno fue 51,601 mg/ml, para el día dos de 23,319 mg/ml y para el día tres de 36,534 mg/ml. Las concentraciones de IgG fueron significativamente superiores el día 1 posparto e inversamente correlacionada con los días posparto (p < 0,05), el número del parto no se encontró asociados a la concentración de IgG (p > 0,05).  La población bovina evaluada produce calostro de buena calidad que puede aprovecharse para la transferencia de inmunidad pasiva creando bancos de calostro.Palabras clave: IgG; ELISA; parto; color; AIMS, FAO; Immunoglobulin; ELISA;  parturition; colourThis study was aimed to correlate the immunoglobulin G (IgG) concentration with protein, minerals and color in 69 bovine colostrums from Bos taurus x Bos indicus crosses from a dual-purpose production system farm on Colombia in the piedemonte llanero during the first three days postpartum. IgG concentration in colostrum had a negative correlation with days postpartum whereas a positive correlation was found with protein, lactose and solid content in whole colostrum. The correlation between whole colostrum color and IgG concentration was positive for the b* value (r=0.182, p=0.024), located it in the range of blues and yellows. Mean IgG concentration for day one was 51,601 mg/ml, 23,319 mg/ml for day two and 36,534 mg/ml for day three. IgG concentrations were significantly higher on day 1 postpartum and inversely correlated with days postpartum (p<0.05). The number of calvings was not associated with IgG concentration (p>0.05). The bovine population evaluated produced good quality colostrum which can be used for transfer of passive immunity by using colostrum banks.Keywords: Immunoglobulin; ELISA; parturition; colour (AIMS;  FAO

Concentración de inmunoglobulina G en calostro bovino en cruces Bos taurus x Bos indicus en los primeros tres días pos parto

This study was aimed to correlate the immunoglobulin G (IgG) concentration with protein, minerals and color in 69 bovine colostrums from Bos taurus x Bos indicus crosses from a dual-purpose production system farm on Colombia in the piedemonte llanero during the first three days postpartum. IgG concentration in colostrum had a negative correlation with days postpartum whereas a positive correlation was found with protein, lactose and solid content in whole colostrum. The correlation between whole colostrum color and IgG concentration was positive for the b* value (r=0.182, p=0.024), located it in the range of blues and yellows. Mean IgG concentration for day one was 51,601 mg/ml, 23,319 mg/ml for day two and 36,534 mg/ml for day three. IgG concentrations were significantly higher on day 1 postpartum and inversely correlated with days postpartum (p0.05). The bovine population evaluated produced good quality colostrum which can be used for transfer of passive immunity by using colostrum banks.O objetivo foi correlacionar a concentração de imunoglobulina G (IgG) com proteína, minerais e cor em 69 amostras de colostro de bovinos da cruza Bos taurus x Bos indicus de um sistema de produção de dupla aptidão do Piedemonte llanero nos primeiros três dias pós-parto. A concentração de IgG no colostro apresentou correlação negativa com os dias pós-parto, e uma correlação positiva com o teor de proteína, lactose e sólidos no colostro total. A correlação entre a cor de colostro todo e a concentração de IgG foi positivo para o valor b* (r = 0,182, p = 0,024), localizado entre a gama de azuis e amarelos. A concentração mediana de IgG dia um foi 51,601 mg / ml, para o dia dois de 23,319 mg / ml e para o dia três de 36,534 mg / ml. As concentrações de IgG foram significativamente maiores no dia um pós-parto e inversamente correlacionado com os dias pós-parto (p 0,05). A população de gado avaliada produz colostro de boa qualidade que pode ser utilizado para a transferência de imunidade passiva a partir de bancos de colostro.El objetivo fue correlacionar la concentración de inmunoglobulina G (IgG) con la proteína, los minerales y el color en 69 calostros de bovinos de cruces Bos taurus x Bos indicus de un predio del sistema de producción doble propósito del piedemonte llanero en los primeros tres días posparto. La concentración de IgG en calostro presentó una correlación negativa con los días posparto, y una correlación positiva con el contenido de proteína, lactosa y sólidos en calostro entero. La correlación entre el color del calostro entero y la concentración de IgG fue positiva para el valor b* (r=0.182, p=0.024), localizado entre el rango de azules y amarillos. La concentración mediana de IgG para el día uno fue 51,601 mg/ml, para el día dos de 23,319 mg/ml y para el día tres de 36,534 mg/ml. Las concentraciones de IgG fueron significativamente superiores el día 1 posparto e inversamente correlacionada con los días posparto (p 0,05). La población bovina evaluada produce calostro de buena calidad que puede aprovecharse para la transferencia de inmunidad pasiva creando bancos de calostro

Seroprevalence of antibodies to Chlamydia abortus and risk factors in cattle from Villavicencio, Colombia

Chlamydia abortus is a Gram-negative obligate intracellular bacterium, responsible for abortions and reproductive problems. The disease has a high zoonotic potential and causes great economic losses in ruminant farmers. A cross-sectional study was carried out with 514 cattle from 24 farms of Villavicencio, Colombia. The blood samples were collected from each individual animal and analyzed by Indirect Elisa for immunoglobulin G (IgG) in blood serum (Idexx Chlamydiosis total Ab test). A serum was considered positive when the optical density (OD) of the sample was ≥30% of that of the positive control serum. Data on potential risk factors associated with the disease were collected through a questionnaire in each farm and analyzed. The individual and herd prevalence was estimated. A risk factors analysis was performed through univariate and multivariable using the software SPSS version 20. The animal level seroprevalence was found to be 47.1% and the herd 91.6%. The prevalence in cattle aged 0–1, 1–3 and >4 years was 23.8%; 31.4% and 51.4% respectively. The risk factors associated with the prevalence of disease were female sex (OR = 2.102 CI: 1.066–4.144), age older than 4 years (OR = 2.707 CI: 1.667–4.394), presence of canines on the farm (OR = 2.556 CI: 1.560–4.189) and retention of placenta (OR = 2.678 CI: 1.670–4.295). A high prevalence was identified, suggesting natural infection where the pathogen could be transmitted to humans at the animal-human interface.Incluye referencias bibliográficas

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

© 2020 Elsevier Ltd. All rights reserved.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran.info:eu-repo/semantics/publishedVersio